主 办:北 京 中 医 药 大 学
ISSN 1006-2157 CN 11-3574/R

北京中医药大学学报 ›› 2019, Vol. 42 ›› Issue (6): 514-522.doi: 10.3969/j.issn.1006-2157.2019.06.014

• 临床研究 • 上一篇    下一篇

养血清脑颗粒与尼莫地平治疗慢性脑供血不足疗效及安全性的Meta分析

常泽, 韩振蕴#, , 田丹枫, 高强, 张丹丹, 林景峰, 王一浩, 刘甘露, 王育纯, 胡文悦, 马华萍   

  1. 北京中医药大学东方医院 北京 100078
  • 出版日期:2019-06-05 发布日期:2019-06-05
  • 通讯作者: 韩振蕴,女,博士,主任医师,博士生导师,研究方向:中医脑病的临床与基础研究, E-mail:tohanzhenyun@sina.com
  • 作者简介:常泽,男,在读硕士生
  • 基金资助:
    国家自然科学基金资助项目(No.81673910)

Meta-analysis of the efficacy and safety of Yangxue Qingnao Granule and nimodipine in the treatment of chronic cerebral circulation insufficiency*

Chang Ze,Han Zhenyun#,Tian Danfeng,Gao Qiang,Zhang Dandan,Lin Jingfeng,Wang Yihao, Liu Ganlu, Wang Yuchun,Hu Wenyue,Ma Huaping   

  1. Dongfang Hospital, Beijing University of Chinese Medicine, Beijing 100078, China
  • Online:2019-06-05 Published:2019-06-05
  • Contact: Prof. Han Zhenyun, Ph.D., Doctoral supervisor. Dongfang Hospital, Beijing University of Chinese Medicine, Building 6, Fangzhuang Fangxingguan, Fengtai District, Beijing, 100078. E-mail: tohanzhenyun@sina.com

摘要: 目的 系统评价养血清脑颗粒与尼莫地平治疗慢性脑供血不足的疗效及安全性。方法 计算机检索CNKI、Wanfang、VIP、CMB、PubMed、The Cochrane library和Embase数据库,收集养血清脑颗粒组与尼莫地平组治疗慢性脑供血不足的随机对照试验(RCT)。由2名研究者根据纳入排除标准和Cochrane协作网的“偏倚风险评估工具”进行文献筛选和文献质量评价后,运用RevMan5.3软件对纳入RCT研究进行Meta分析。结果 纳入18项RCT研究,共1 457例患者,其中养血清脑颗粒组744例,尼莫地平组713例。养血清脑颗粒组总有效率优于尼莫地平组(OR=4.88,95%CI [3.63~6.55],P<0.000 01),且养血清脑颗粒组治疗慢性脑供血不足在1个月(OR=4.52,95%CI [3.30~6.19],P<0.000 01)、3个月(OR=8.24,95%CI [3.45~19.67],P<0.000 01)的总有效率均优于尼莫地平组。养血清脑颗粒组较尼莫地平组可有效降低纤维蛋白酶原(MD=1.07,95%CI [0.84~1.30],P<0.000 01)和血浆比黏度指标(MD=0.34,95%CI [0.30~0.37],P<0.000 01)。结论 养血清脑颗粒治疗慢性脑供血不足患者的疗效优于尼莫地平。因受纳入研究质量和数量及试验设计欠规范所限,上述结论仍需高质量、大样本、多中心的临床研究加以验证。

关键词: 养血清脑颗粒, 尼莫地平, 慢性脑供血不足, 系统评价, Meta分析

Abstract: Objective To evaluate the efficacy and safety of Yangxue Qingnao Granule and nimodipine in the treatment of chronic cerebral circulation insufficiency.Methods The databases of CNKI, Wanfang, VIP, CMB, PubMed, The Cochrane library and Embase were searched, and the randomized controlled trials (RCT) of Yangxue Qingnao Granule group and nimodipine group for the treatment of chronic cerebral circulation insufficiency were collected.Two researchers conducted literature screening and literature quality evaluation according to the inclusion and exclusion criteria and the “risk of bias assessment tool” of the Cochrane collaboration. Then, the included RCT studies were meta-analyzed using RevMan 5.3 software.Results A total of 1 457 patients were included in 18 RCT studies, including 744 patients in the Yangxue Qingnao Granule group and 713 patients in the nimodipine group. Meta analysis results show that the Yangxue Qingnao Granule group total effective rate is better than that of nimodipine group (OR = 4.88, 95% CI [3.63, 6.55], P<0.000 01), and total effective rates of Yangxue Qingnao Granule group for the treatment of chronic cerebral circulation insufficiency in a month (OR = 4.52, 95% CI [3.30, 6.19], P<0.000 01) and 3 months (OR=8.24, 95% CI [3.45, 19.67], P<0.000 01) were superior to those of nimodipine group. Compared with the nimodipine group, the Yangxue Qingnao Granule group was able to effectively reduce the fibrinogen (MD=1.07, 95%CI [0.84, 1.30], P<0.00001) and the plasma viscosity ratio index (MD=0.34, 95%CI [0.30, 0.37], P<0.000 01).Conclusion Yangxue Qingnao Granule is better than nimodipine in treating patients with chronic cerebral circulation insufficiency. Due to the limitations of the quality and quantity of included studies and the lack of standard experimental design, the above conclusions still need to be verified by high-quality, large-sample and multi-center clinical studies.

Key words: Yangxue Qingnao Granule, nimodipine, chronic cerebral circulation insufficiency, systematic evaluation, Meta analysis

中图分类号: 

  • R255.3